• KOL
    • Cocaine Dependence
    • Thomas R Kosten
    • THOMAS R Kosten: Influence Statistics

       THOMAS R Kosten

      THOMAS R Kosten

      Show email address

      Baylor College of Medicine, Houston, TX, USA | Department of Psychiatry, Baylor College of Medicine, Houston, TX USA | Department of Psychiatry, Neuroscience, Pharmacology, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      THOMAS R Kosten:Expert Impact

      Concepts for whichTHOMAS R Kostenhas direct influence:Cocaine dependence,Cocaine abuse,Substance abuse,Opioid dependence,Cognitive deficits,Cocaine vaccine,Cocaine addiction,Schizophrenic patients.

      THOMAS R Kosten:KOL impact

      Concepts related to the work of other authors for whichfor which THOMAS R Kosten has influence:Posttraumatic stress disorder,Cocaine dependence,Substance abuse,Smoking cessation,Chronic pain,Depressive symptoms,Oxidative stress.

      KOL Resume for THOMAS R Kosten

      Year
      2022

      Baylor College of Medicine, Houston, TX, USA

      Michael E. DeBakey VA Medical Center, Houston, TX

      2021

      Department of Pharmacology, Baylor College of Medicine, Houston, TX, United States

      Michael E. DeBakey VA Medical Center, Houston TX, USA.

      Texas Institute of Measurement Evaluation and Statistics, University of Houston, Houston, TX USA

      Baylor College of Medicine.

      The American Journal on Addictions.

      2020

      Baylor College of Medicine, Houston, TX.

      Editor, The American Journal on Addictions.

      Mental Health Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.

      Michael E. DeBakey VA Medical Center, Houston, Texas

      2019

      Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA

      Michael E. DeBakey V.A. Medical Center, Houston, Texas

      Baylor College of Medicine, Houston, TX

      2018

      Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.

      Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

      2017

      Michael E DeBakey VA Medical Center HoustonTexas

      Baylor College of Medicine Menninger Department of Psychiatry and Behavioral Sciences Houston Texas

      2016

      Pavlov First St.Petersburg State Medical University, St.Petersburg, Bekhterev St.Petersburg Research Psychoneurilogical Institute, St.Petersburg, Serbsky Federal Medical research Center for Psychiatry and Narcology, Moscow, Russia.

      LI, SHORTER, and KOSTEN: Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX SHORTER and KOSTEN: Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX

      From the Department of Psychiatry, Baylor College of Medicine, Houston.

      Michael DeBakey Veterans Affairs Medical Center, Houston, Texas.

      2015

      Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, & Michael E. DeBakey VA Medical Center, Houston, TX, USA

      Mental Health Care Line Michael E. DeBakey V.A. Medical Center Houston Texas

      2014

      Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas

      Baylor College of Medicine (United States)

      Sign-in to see all concepts, it's free!
      Sample of concepts for which THOMAS R Kosten is among the top experts in the world.
      Concept World rank
      clinical phenotypes dyskinesia #1
      multivariate approaches values #1
      ondansetron promise #1
      pathophysiology ginkgo biloba #1
      site oral fluids #1
      351±31 #1
      positive urines individuals #1
      cmb cmp #1
      methadonemaintained patients #1
      cocainefree urines percentage #1
      addicts perceptions environment #1
      lta1 dmlt #1
      cud volunteers #1
      mdd ncm #1
      gaba medications #1
      disease habenula humans #1
      cocainepositive urines #1
      cocaine p00001 #1
      seropositive cocaine #1
      anticocaine vaccines #1
      oud agonist treatment #1
      val66met gene polymorphism #1
      volunteers pramipexole #1
      patients rs6473797 variant #1
      dopamine doxazosin #1
      isradipine male methadone #1
      cocaine addiction objective #1
      3x week differences #1
      withdrawal symptoms score #1
      buprenorphine 2 #1
      lu habenula #1
      cocaine p005 #1
      structural differences sud #1
      betablockers antiseizure agents #1
      aa drd2 #1
      ideal pharmacotherapy bpd #1
      klh6sm #1
      medicine questionnaires temperance #1
      doxazosin cud #1
      gbp relapse #1
      methadone lower doses #1
      evidence alcoholism treatment #1
      dmlt fentanyl #1
      trx cognitive performance #1
      interactions thermodynamic properties #1
      studies crash phase #1
      genetics data pgl #1
      сс #1
      neurobiological adaptations psychostimulants #1
      heroinrelated experiment #1
      Sign-in to see all concepts, it's free!

      Prominent publications by THOMAS R Kosten

      KOL-Index: 14378

      BACKGROUND: Buprenorphine, a partial mu-agonist and kappa-antagonist, has been proposed as an alternative to methadone for maintenance treatment of opioid dependence, especially for patients with concurrent cocaine dependence or abuse. This study evaluated whether higher maintenance doses of buprenorphine and methadone are superior to lower doses for reducing illicit opioid use and whether buprenorphine is superior to methadone for reducing cocaine use.

      METHODS: A total of 116 subjects ...

      Known for Maintenance Treatment | Buprenorphine Methadone | Cocaine Abuse | Illicit Opioid | Partial Agonist
      KOL-Index: 12731

      OBJECTIVE: Physicians may prescribe buprenorphine for opioid agonist maintenance treatment outside of narcotic treatment programs, but treatment guidelines for patients with co-occurring cocaine and opioid dependence are not available. This study compares effects of buprenorphine and methadone and evaluates the efficacy of combining contingency management with maintenance treatment for patients with co-occurring cocaine and opioid dependence.

      METHOD: Subjects with cocaine and opioid ...

      Known for Contingency Management | Opioid Dependence | Methadone Buprenorphine | Maintenance Treatment | Longer Periods
      KOL-Index: 11957

      Several lines of evidence suggest that central brain-derived neurotrophic factor (BDNF) modulates food intake, metabolism, and increases in body weight. Reports have also shown that serum BDNF is altered in schizophrenic patients treated with antipsychotics. This study aimed to determine if there was a relationship between BDNF and antipsychotic-induced weight gain in patients with chronic schizophrenia. Serum BDNF was measured in 124 schizophrenia patients chronically treated with ...

      Known for Serum Bdnf | Schizophrenic Patients | Weight Gain | Chronic Schizophrenia | Typical Antipsychotics
      KOL-Index: 11694

      BACKGROUND: Schizophrenic patients have high rates of cigarette smoking compared with the general population. We compared sustained-release (SR) bupropion with placebo for smoking cessation in patients with schizophrenic disorders. We also examined how antipsychotic class predicts smoking cessation outcomes with bupropion.

      METHODS: Thirty-two subjects meeting DSM-IV criteria for schizophrenia or schizoaffective disorder and nicotine dependence were randomized to bupropion SR (BUP, 300 ...

      Known for Smoking Cessation | Bupropion Placebo | Abstinence Rates | Schizophrenic Patients | Nicotine Dependence
      KOL-Index: 11651

      Cognitive impairment occurs in both schizophrenia and diabetes. There is currently limited understanding whether schizophrenia with diabetes has more serious cognitive deficits than schizophrenia without diabetes or diabetes only. This study assessed cognitive performance in 190 healthy controls, 106 diabetes only, 127 schizophrenia without diabetes and 55 schizophrenia with diabetes. This study was conducted from January 2008 to December 2010. Compared to healthy controls, all patient ...

      Known for Cognitive Deficits | Diabetes Schizophrenia | Casecontrol Study | Studies Cognition | Schizophrenic Psychology
      KOL-Index: 11617

      S100B is a calcium-binding protein, mainly produced and secreted by astrocytes, and it mediates the interaction among glial cells and between glial cells and neurons. Recently, several studies have shown increased serum 100B levels in patients with schizophrenia, suggesting that S100B might be relevant to the pathophysiology of schizophrenia. To examine the potentially differential effect of clozapine compared to typical antipsychotics on serum S100B and the relationship between S100B ...

      Known for S100b Levels | Patients Schizophrenia | Increased Serum | Glial Cells | Calcium Binding
      KOL-Index: 11520

      RATIONALE: Heroin use and withdrawal cause abnormality in the endocrine system. However, the time course of neuroendocrine alterations in heroin addicts during pharmacologically unassisted withdrawal is still unclear.

      OBJECTIVES: To investigate alterations in cortisol, adrenocorticotrophic hormone (ACTH), beta-endorphin (beta-EP), leptin, and neuropeptide Y (NPY) during the first month of abstinence in heroin addicts.

      METHODS: Twelve heroin addicts and eight matched healthy control ...

      Known for Heroin Addicts | Drug Craving | Npy Anxiety | Cortisol Levels | Beta Endorphin
      KOL-Index: 11267

      BACKGROUND: GABAergic medications appear to reduce the reinforcing effects of cocaine by attenuating cocaine-induced dopamine release. This study evaluated gabapentin and tiagabine compared to placebo in reducing cocaine taking behavior.

      METHODS: A total of 76 treatment seeking, cocaine dependent, methadone-treated, predominately Caucasian male subjects were randomly assigned to tiagabine 24 mg/day (N=25), gabapentin 2400 mg/day (N=26) or placebo (N=25) in a 10-week double-blind ...

      Known for Placebo Gabapentin | Tiagabine Cocaine | Treatment Retention | 10 Week | Aminobutyric Acid
      KOL-Index: 11228

      RationaleCatechol-O-methyltransferase (COMT) is an enzyme involved in the degradation and inactivation of the neurotransmitter dopamine, which is important in mediating drug reward such as nicotine in tobacco smoke. Different COMT alleles encode enzyme whose activity varies from three- to fourfold that may affect dopamine levels and alter subjective effects of nicotine. Recent evidence also suggests that a COMT polymorphism may be especially important in determining an individual’s ...

      Known for Smoking Initiation | Male Smokers | Comt Polymorphism | Nicotine Dependence | Functional Catechol
      KOL-Index: 11107

      Studies suggest that a functional polymorphism of the brain-derived neurotrophic factor gene (BDNF Val66Met) may mediate hippocampal-dependent cognitive functions. A few studies have reported its role in cognitive deficits in schizophrenia including its association with peripheral BDNF levels as a mediator of these cognitive deficits. We assessed 657 schizophrenic inpatients and 445 healthy controls on the repeatable battery for the assessment of neuropsychological status (RBANS), the ...

      Known for Bdnf Val66met | Gene Polymorphism | Normal Controls | Schizophrenic Patients | Schizophrenia Association
      KOL-Index: 11076

      OBJECTIVE: The α7 nicotinic acetylcholine receptor (nAChR) is associated with cognitive and P50 auditory gating deficits in schizophrenia, and α7 nAChR agonists can potentially reverse these deficits. The authors examined multiple dosages of tropisetron, a partial agonist at the nAChR, for short-term effects on cognition and P50 deficits in schizophrenia.

      METHOD: In a randomized double-blind design, 40 nonsmoking patients with schizophrenia who had P50 ratios greater than 0.5 and were ...

      Known for Auditory Gating | Tropisetron Treatment | Cognitive Deficits | Nicotinic Schizophrenia | Α7 Nachr Agonists
      KOL-Index: 11015

      The high prevalence of smoking in schizophrenia of European background may be related to smoking's reducing clinical symptoms and medication side effects. Because smoking prevalence and its associations with clinical phenotypes are less well characterized in Chinese than European patients with schizophrenia, we assessed these smoking behaviors using clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence (FTND) in 776 Chinese male schizophrenia and 560 ...

      Known for Cigarette Smoking | Chronic Schizophrenia | Clinical Phenotypes | Chinese Population Prevalence | Nicotine Dependence

      Key People For Cocaine Dependence

      Top KOLs in the world
      #1
      Charles P O'Brien
      cocaine dependence substance abuse ethanol consumption
      #2
      Bruce James Rounsaville,
      opiate addicts substance abuse cocaine dependence
      #3
      THOMAS R Kosten
      cocaine dependence substance abuse cognitive deficits
      #4
      Nora D Volkow
      positron emission tomography cocaine abusers drug addiction
      #5
      Anthony Thomas McLellan
      substance abuse addiction treatment cocaine dependence
      #6
      Herbert D Kleber
      opiate addicts cocaine abuse methadone maintenance

      Baylor College of Medicine, Houston, TX, USA | Department of Psychiatry, Baylor College of Medicine, Houston, TX USA | Department of Psychiatry, Neuroscience, Pharmacology, and Immunology and Rheumatology, Baylor College of Medicine, Houston, TX | De

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.